What Dacarex Treats: Main Uses and Benefits

Dacarex, based on the active ingredient dacarbazine, is used to provide systemic support in the management of cancers characterized by the aggressive, uncontrolled growth of malignant cells. It is applied in specialized oncology settings to help address the challenge of disease progression. This treatment is utilized for various types of cancer, including metastatic malignant melanoma and as a component of therapeutic regimens for Hodgkin's lymphoma.

The medication is commonly applied in patients facing advanced-stage cancers that present with a significant symptomatic burden associated with disease progression. It is relevant in clinical settings marked by heightened disease severity, such as when the cancer has spread to distant sites. Applying this agent offers therapeutic benefit by helping to manage the condition, which plays a role in supporting an objective clinical response.

“This systemic treatment is often applied in contexts where aggressive anti-proliferative support is required to stabilize the disease.”

This supportive effect contributes to easing the overall symptom load by supporting the management of the tumor burden, assisting in the stabilization of the disease, and supports general well-being during symptomatic phases.

Quick Fact: Support for Advanced Disease
Dacarex helps to slow the progression of malignant disease, offering support that is relevant for managing advanced and metastatic disease.

Regulatory References

1. MedlinePlus Drug Information

Who Can and Cannot Use Dacarex?

Dacarex (dacarbazine) eligibility is strictly defined by regulatory agencies and is allowed for adult patients managing metastatic malignant melanoma and advanced Hodgkin's disease. Use is highly restricted or prohibited for several populations, based on the official prescribing information.

Eligibility Status	Affected Population
Contraindicated	Patients with known hypersensitivity to the drug or its excipients, or those who are pregnant or breastfeeding. Use is also prohibited for patients with a history of severe myelosuppression (bone marrow depression).
Conditional Use	Patients with pre-existing hepatic and/or renal insufficiency require careful function monitoring, as the drug's elimination may be prolonged. Use also requires caution in patients with an active infection.

Age-Related Restrictions

The official labeling states that use in the pediatric age group is not established, and no specific recommendations are available due to insufficient clinical data. Similarly, experience in older adults is limited, meaning specific dosage instructions for this age group are not available in regulatory documents.

Interactions with other medicines and products

The official interaction profile for Dacarex (Dacarbazine) defines combinations that are contraindicated, those that modify drug exposure, and substances that carry a risk of additive systemic effects, as established in regulatory labeling.

---

Interaction Scope

Feature	Regulatory Summary Statement
Prohibited Combinations	Co-administration is restricted with Fotemustine and Live or Live-attenuated Vaccines.
Metabolic Basis	Dacarex is metabolized by hepatic CYP enzymes, specifically CYP1A1, CYP1A2, and CYP2E1.
Exposure-Altering Agents	Phenytoin is not recommended due to increased drug metabolism; Interleukin-2 is documented to increase Dacarex clearance.
Pharmacodynamic Risks	Additive systemic effects occur with other bone-marrow depressants and antineoplastic agents, increasing the risk of toxicity.
Timing Rule	A separation of one week is required between Dacarex and Fotemustine administration.
Dietary Restriction	The co-consumption of alcohol is formally classified as unsafe.

---

Official Interaction Statements

• The use of live vaccines is prohibited due to the risk of serious infection in the patient population.
• The combination with Phenytoin is officially not recommended due to its role as an enzyme inducer, which may alter the exposure of Dacarex.
• The risk of hepatic toxicity and additive bone marrow depression is a regulatory consideration when combining Dacarex with other antineoplastic or bone-marrow depressant drugs.
• Interleukin-2 co-administration is associated with an increase in Dacarex's drug clearance and volume of distribution.
• Hepatic dysfunction is a population-specific note, as slower clearance in patients with liver disease may increase the drug's effects.

---

Connection to the overall interaction profile

The regulatory documents establish the interaction profile through mandatory restrictions, including contraindicated combinations and a specific dosing separation requirement. The profile formally details pharmacokinetic interactions involving specific CYP enzymes and agents that modify drug exposure, alongside pharmacodynamic warnings concerning additive systemic toxicity risks.

How Dacarex Works

Metabolic Activation and the Alkylation Cascade

Dacarex (Dacarbazine) functions as an inactive prodrug until it undergoes hepatic bioactivation. Cytochrome P450 enzymes in the liver catalyze N-demethylation, transforming the molecule into the highly reactive methyldiazonium ion. This final active species is responsible for alkylation, a chemical reaction that covalently modifies the DNA of cells, primarily at Guanine bases. This molecular modification creates lesions and cross-links in the DNA structure.

DNA Damage Recognition and Programmed Cell Death

The chemical damage to the DNA is recognized by cellular integrity systems, such as the Mismatch Repair (MMR) pathway, which interprets the damage as a signal to halt the cell's ability to replicate. This action enforces cell cycle arrest and subsequently triggers apoptosis (programmed cell death). This biological sequence results in the physiological consequence of induced cell death in high-proliferation cells. The mechanistic activity is constrained if the DNA repair enzyme MGMT is highly expressed, or if the MMR system is non-functional, as either condition prevents the necessary cytotoxic cascade.

How Dacarex is Used: Official Administration Guidelines

Dacarex (dacarbazine) is administered exclusively via the intravenous (IV) route under the supervision of a physician experienced in cancer chemotherapy. It is supplied as a powder for injection that requires reconstitution and, often, further dilution before use.

Official Dosing and Scheduling

Treatment with Dacarex follows defined cyclic regimens based on the patient's body surface area (mg/m^2) or weight (mg/kg). The medicine is delivered in courses, followed by scheduled rest periods.

Indication	Standard Adult Regimens	Cycle Frequency
Metastatic Malignant Melanoma	250 mg/m^2 daily for 5 days; OR 2 to 4.5 mg/kg daily for 10 days; OR 850 mg/m^2 on Day 1	Repeat every 3 or 4 weeks
Hodgkin's Disease	150 mg/m^2 daily for 5 days; OR 375 mg/m^2 on Day 1 (in combination therapy)	Repeat every 4 weeks or 15 days

Preparation and Administration Conditions

1. Reconstitution and Dilution: The powder is first reconstituted with Sterile Water for Injection to achieve a solution of 10 mg/mL. This solution may then be further diluted using 5% Dextrose Injection or 0.9% Sodium Chloride Injection for infusion.
2. Infusion Rate: Smaller doses (up to 200 mg/m^2) may be administered by slow IV push (over about 1 minute). Larger single doses must be given as an IV infusion over 15 to 30 minutes.
3. Light Sensitivity: The reconstituted solution is light-sensitive and must be appropriately protected during administration.
4. Special Use: Restriction of oral food intake for 4 to 6 hours prior to treatment may be recommended as part of the procedure. No specific dose adjustments for older adults or children are typically provided in official labels.

Research Evidence / Overview of Studies for Dacarex

Evidence for Use in Metastatic Malignant Melanoma

This section summarizes the research base for Dacarex in advanced melanoma, focusing on the types of clinical trials conducted, the survival and response outcomes that researchers measured, and the study populations involved. Dacarex was studied for use in patients with advanced, metastatic malignant melanoma, often within the structure of Randomized Controlled Trials (RCTs). In these research scenarios, Dacarex alone or as part of a combination treatment was frequently used as a comparator arm in trials exploring newer agents. Studies monitored the Objective Response Rate (ORR), which measures documented tumor reduction, and data show patterns related to Progression-Free Survival (PFS) and Overall Survival (OS).

Findings describe patterns observed in these studies where specific percentages of patients achieved a measured Objective Response Rate. However, for this condition, the evidence is limited and findings were mixed regarding the consistency of high response rates when Dacarex was observed in studies as a single agent. The majority of recent research has positioned Dacarex as a reference benchmark for comparison, meaning there is limited information regarding its single-agent use in modern treatment contexts.

Evidence as a Component for Hodgkin's Lymphoma Regimens

This part will describe the evidence structure supporting the use of Dacarex within established multi-drug chemotherapy protocols for Hodgkin's lymphoma. Dacarex was studied for this condition strictly as an integrated component of multi-agent protocols, such as ABVD. The studies explored the entire regimen's impact on outcomes, including the documented Complete Remission Rate (CR) and the Duration of Remission. Research was conducted on large cohorts of adults and adolescents, describing long-term follow-up and the durability of the outcomes related to functional balance.

Studies report how Complete Remission and long-term Progression-Free Survival were tracked in the established combination protocols. Crucially, because Dacarex is an integrated part of these regimens, it was never studied or administered alone for this condition. Therefore, the specific contribution of Dacarex itself, separate from the other components, cannot be isolated or determined by the existing research structure.

Key Studies & References

1. Dacarbazine for Injection, USP (DTIC-Dome) Official Prescribing Information / Label
2. Treatment of Stage I and II Hodgkin's Lymphoma With ABVD Chemotherapy: Results After 7 Years of a Prospective Study

Common questions about Dacarex (FAQ)

Q: Does Dacarex carry a 'black box warning' in the US or similar caution in other regions?

Yes, the US Food and Drug Administration (FDA) label for Dacarex includes a prominent Boxed Warning, which is a regulatory measure used to highlight potential serious or life-threatening adverse reactions. This warning specifically emphasizes the risk of severe bone marrow suppression (myelosuppression) and a rare but potentially fatal form of liver damage (hepatic necrosis). This warning signals the necessity of close monitoring by a healthcare professional during treatment.

Q: How long does Dacarex stay in your system after the last dose?

The medicine's elimination from the body, measured by its half-life, occurs in two phases. In patients with normal liver and kidney function, the initial phase of clearance is about 19 minutes. The final or terminal phase of elimination is estimated to take approximately 5 hours according to pharmacokinetics data.

Q: What is the official process for reporting a suspected side effect related to Dacarex?

Official documents advise that suspected side effects, also known as adverse reactions, should be reported to the relevant regulatory authority. In the US, this typically involves contacting the medicine’s manufacturer or reporting directly to the FDA through their MedWatch adverse event reporting program. The reporting process helps regulatory bodies monitor the medicine's safety profile over time.

Q: Does Dacarex have any known impact on fertility?

Information regarding the specific effect of Dacarex on human reproductive capacity is not fully established in regulatory documents. However, animal studies suggest that the drug has the potential to cause damage to sperm. For this reason, the product information states that adequate methods of contraception are required during and for a period following treatment.

Q: Can Dacarex affect sleep patterns or cause insomnia?

Official regulatory documents do not specifically list insomnia or sleep pattern changes as common or rare adverse reactions of Dacarex. However, the medicine has been associated with some effects on the nervous system, such as headache, confusion, and a feeling of lethargy (sluggishness).

Q: What is the official guidance if a dose of Dacarex is accidentally missed?

Because Dacarex is an intravenous medicine administered by healthcare professionals in a clinical setting, patient guidance centers on maintaining the treatment schedule. Official documents state that if a treatment is missed, the patient's care team should be contacted immediately for instruction.

Q: What is the significance of the medication's half-life?

The half-life is a measure of the rate at which the active drug is cleared from the bloodstream. Official product information indicates that the half-life of Dacarex is often prolonged (meaning it stays in the body longer) in patients who have existing kidney or liver dysfunction.

Q: Is Dacarex described as a controlled substance in any country?

Regulatory checks confirm that the active ingredient, Dacarbazine, is generally not classified as a controlled medication by the Drug Enforcement Administration (DEA) in the United States. This means it is not subject to the special legal scheduling rules that apply to substances with potential for abuse or dependence.

How to Store and Dispose of Dacarex?

The official storage and disposal instructions for Dacarex (dacarbazine) strictly follow regulatory guidelines to maintain stability and ensure safety.

---

Storage Conditions

The unopened vials must be stored in a refrigerator at a temperature between 2 C and 8 C (36 F to 46 F) and must not be frozen. The medicine is light-sensitive and must be kept in its original container and protected from light. As a child safety precaution, Dacarex must be stored out of the sight and reach of children.

---

Disposal Requirements

Due to its classification as a cytotoxic agent, all unused product and related waste must follow specific local procedures for cytotoxic agents and must not be disposed of via wastewater or household trash. Disposal must be managed according to professional and environmental protocols.